February 6, 2015

Biogazelle strengthens its board of directors

On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on http://bgzlle.com/2bCDGtm). Today, Biogazelle announces that it has strengthened its board with two directors representing the new investors and also announces its intention to propose the nomination of Nick McCooke and Jim Van heusden as non-executive directors to the next shareholder meeting.

January 27, 2015

Biogazelle has established a quality management system and is ISO 17025 accredited for gene expression services

Biogazelle is a Ghent University spin-off company founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. With a proven track record in gene expression studies, Biogazelle is at the forefront of transcriptome analyses using state-of-the-art laboratory methods, including RNA sequencing and RT-qPCR.

October 24, 2014

Meet us at the Bio-Europe 2014 meeting in Frankfurt

Biogazelle participates at the Bio-Europe 2014 meeting in Frankfurt from November 3-5, 2014.
This forum creates the opportunity to discuss your gene expression projects and research partnerships.
Please send an email to info@biogazelle.com if you want to set up a meeting. We can then assess if our services can support your research. We are open to discuss subcontractor work for or partnerships in Horizon 2020 projects.

October 6, 2014

UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth

Qbic Arkiv Fund, Foundation Majoie and SOFI invest 2.0 million EUR in UGent spin-off Biogazelle, a company that offers software and laboratory services for gene expression analysis. Biogazelle will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types, and to expand its commercial activities.